Table 3.
Univariate Cox regression of prognostic factors for biochemical relapse
| Factors | Univariate Cox regression | ||
|---|---|---|---|
| HR | 95% CI | p | |
| Initial tumor stage (T2c ≤ vs. ≥ T3a) | 0.67 | 0.43–1.05 | 0.08 |
| Initial nodal status (N0 vs. N1) | 0.67 | 0.43–1.05 | 0.08 |
| Initial Gleason score (7a ≤ vs. ≥ 7b) | 0.66 | 0.39–1.08 | 0.10 |
| Initial resection status (R0 vs. R1) | 1.02 | 0.67–1.58 | 0.91 |
| PSA persistence > 0.1 ng/mL after RP (yes vs. no) | 1.59 | 1.04–2.43 | 0.03* |
| PSA level at PMSA-PET imaging (> 0.8 ng/mL vs. ≤ 0.8 ng/mL) | 0.51 | 0.32–0.79 | 0.003* |
| Age at relapse (continuous) | 1.00 | 0.98–1.03 | 0.90 |
| Local recurrence at PSMA-PET imaging (no vs. yes) | 1.46 | 0.95–2.26 | 0.09 |
| Pelvic lymph node lesions at PSMA-PET imaging (no vs. yes) | 1.05 | 0.69–1.60 | 0.82 |
| Distant metastases at PSMA-PET imaging | |||
| Lymph nodes (no vs. yes) | 0.80 | 0.40–1.60 | 0.53 |
| Bone (no vs. yes) | 0.38 | 0.24–0.62 | 0.0001* |
| Visceral (no vs. yes) | 0.19 | 0.05–0.78 | 0.02* |
| Total number of lesions (1 versus > 1) | 0.96 | 0.58–1.59 | 0.87 |
| Use of additive ADT | 2.56 | 1.51–4.36 | 0.0005* |
PSA, prostate-specific antigen; RP, radical prostatectomy; PSMA-PET, prostate-specific membrane antigen-positron emission tomography; ADT, androgen deprivation therapy; HR, hazard ratio; 95% CI, 95% confidence interval
*Significant result